Pulmonx Corporation (LUNG) Reports In-Line Q1 EPS; Offers FY23 Revenue Guidance
Pulmonx Corporation (NASDAQ: LUNG) reported Q1 EPS of ($0.42), in-line with the analyst estimate of ($0.42). Revenue for the quarter came in at $14.5 million versus the consensus estimate of $13.58 million.
GUIDANCE:
Pulmonx Corporation sees FY2023 revenue of $63-65 million, versus the consensus of $64.4 million.
For earnings history and earnings-related data on Pulmonx Corporation (LUNG) click here.
